Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL6906729 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL6399485 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL29592605 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL3396683 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL8711577 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL8714192 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL5474538 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL31011150 | 0.94 | — | — | |
| Phosphoric Acid SCHEMBL7968394 | 0.94 | SLC34A1 (0.60) | — | |
| Phosphoric Acid SCHEMBL2761582 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021037127-A1 | BENZIMIDAZOLE SUBSTITUTION-BASED PHENYL N-BUTYRAMIDE COMPOUND AND PREPARATION METHOD THEREFOR | 上海特化医药科技有限公司 | 2021-03-04 | — | — | WO | claimed |
| US-11246932-B2 | Prostaglandin compositions and methods for the treatment of vasospasm | NEXMED HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2021037127-A1 | BENZIMIDAZOLE SUBSTITUTION-BASED PHENYL N-BUTYRAMIDE COMPOUND AND PREPARATION METHOD THEREFOR | 上海特化医药科技有限公司 | 2021-03-04 | — | — | WO | disclosed |
| US-20190076529-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM | NEXMED HOLDINGS, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20150272875-A1 | ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION | NEXMED HOLDINGS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9066854-B2 | Alprostadil and dyclonine for treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9060929-B2 | Alprostadil for treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9056044-B2 | Alprostadil and lidocaine treatment of premature ejaculation | NEXMED HOLDINGS, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150011585-A1 | ALPROSTADIL AND DYCLONINE FOR TREATMENT OF PREMATURE EJACULATION | NEXMED HOLDINGS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011638-A1 | ALPROSTADIL AND LIDOCAINE TREATMENT OF PREMATURE EJACULATION | NEXMED HOLDINGS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| CN-1137086-C | 2-aminopropane-1, 3-diol compound, use thereof as medicine and synthetic intermediate thereof | ������ҩ��ʽ���� | 2004-02-04 | — | — | CN | disclosed |
| US-20030220292-A1 | Treatment of erectile dysfunction | NEXMED (HOLDINGS), INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003070281-A1 | PROSTAGLANDIN COMPOSITION FOR THE TREATMENT OF ERECTILE DYSFUNCTION | NEXMED (HOLDINGS), INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030134903-A1 | Prostaglandin compositions and methods of treatment for male erectile dysfunction | NEXMED (HOLDINGS), INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003022310-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION | NEXMED HOLDINGS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1255552-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION | Nexmed Holdings, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6414028-B1 | MIXTURE WITH SKIN PENETRATION INTENSIFIER, POLYSACCHARIDE GUM AND BUFFER | NEXMED HOLDINGS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20020045665-A1 | Prostaglandin compositions and methods of treatment for male erectile dysfunction | NEXMED (HOLDINGS), INC. | 2002-04-18 | — | — | US | disclosed |
| WO-2001051053-A1 | PROSTAGLANDIN COMPOSITIONS AND METHODS OF TREATMENT FOR MALE ERECTILE DYSFUNCTION | NEXMED HOLDINGS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| CN-1259117-A | 2-aminopropane-1, 3-diol compound, use thereof as medicine and synthetic intermediate thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2000-07-05 | — | — | CN | disclosed |